N/A N=130 Staging and Outcome Depending on Surgical Treatment in Adenocarcinomas of the Oesophagogastric Junction
Esophageal Carcinoma
Primary: Overall Survival — 12; 11; 13 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=25 INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
Pancreatic Cancer Non-resectable · Pancreatic Cancer Metastatic
Primary: Disease Control Rate (DCR) at 4 Months Using RECIST 1.1 — 2 Participants
Phase 2 N=16 Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
Recurrent Oral Cavity Adenoid Cystic Carcinoma · Recurrent Salivary Gland Carcinoma · Salivary Gland Adenoid Cystic Carcinoma
Primary: Confirmed Response Rate (Complete Response + Partial Response) According to RECIST Version 1.1 — 0 percentage of patients
Phase 2 N=229 Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Pancreatic Adenocarcinoma
Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants
Phase 2 N=34 Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Metastatic Adenoid Cystic Carcinoma · Progressive Disease · Recurrent Adenoid Cystic Carcinoma
Primary: Assess the Objective Response Rate (ORR) to Axitinib and Avelumab Combination According to RECIST 1.1 Criteria. — 18 percentage of participants
Phase 2 N=38 Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma
Primary: Number of Participants Alive With and Without Disease Progression — 4; 6; 28 Participants
N/A N=740 I-scan for Adenoma Detection
Colorectal Adenomatous Polyps
Primary: Number of Participants With Conventional Adenoma and Sessile Serrated Adenoma/Polyp Detected — 208; 171 Participants
Phase 2 N=39 Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers
High-grade Salivary Gland Carcinoma · High-grade Salivary Gland Mucoepidermoid Carcinoma · Low-grade Salivary Gland Carcinoma
Primary: Objective Response Rates (Partial and Complete Responses) — 0 participants
Phase 2 N=33 Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma
Primary: Overall Response Rate — 0; 3; 25; 4 Participants
Phase 3 N=355 Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
Gastric Cancer · Adenocarcinoma
Primary: Overall Survival (OS) — 5.2; 3.8 months — p=0.0473
N/A N=269 Complete Histologic Resection of Adenomatous Polyps?
Adenomatous Polyps
Primary: Percent of Incompletely Resected Adenomatous Polyps — 10.1 percentage of incomplete resection
Phase 2 N=30 Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma
Recurrent Oral Cavity Adenoid Cystic Carcinoma · Recurrent Salivary Gland Carcinoma · Salivary Gland Adenoid Cystic Carcinoma
Primary: Objective Response According to RECIST 1.1 Criteria — 2; 27; 1 Participants
Phase 2 N=24 Phase II Study of Irinotecan and Panitumumab
Esophageal Cancer
Primary: Response Rate (RR) — 6 percentage of participants
Phase 2 N=18 A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma
Primary: Best Overall Response Rate — 0; 0; 11; 5 Participants
Phase 2 N=37 Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy
Patients With Stage IV or Recurrent Adenocarcinoma of the Lung
Primary: Overall Response Rate — 13.5 percentage of participants
Phase 2 N=60 Vaccine Therapy Combined With Adjuvant Chemoradiotherapy in Treating Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas
Pancreatic Cancer
Primary: Overall Survival — 24.8 Months
Phase 2 N=20 Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum
Cancer of Rectum · Cancer of the Rectum · Neoplasm, Rectum
Primary: Complete Response Rate — 12 Participants
Phase 2 N=36 A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal
Anal Cancer · Rectal Cancer
Primary: Percentage of Participants With Best Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 — 2.8 percentage of participants
Phase 2 N=21 Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma
Primary: Patients Demonstrating Objective Response In Non-Irradiated Lesions (Tumor Size on Scans) — 0; 0 Participants
Phase 2 N=48 ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)
Pancreatic Cancer
Primary: Recurrence Free Survival — 15.6 months
Phase 2 N=46 First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation
Pulmonary Cancer
Primary: Percentage of Participants Who Had an Objective Response Rate(ORR) Based on Response Evaluation Criteria In Solid Tumors (RECIST) Criteria. — 0 Percent of Participants
Phase 2 N=45 Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma
Adenomatous Polyp · Recurrent Colon Cancer · Recurrent Rectal Cancer
Primary: Change in ACF pERK Levels
N/A N=36 Respiratory-gated Stereotactic Body Radiation Therapy for Adenocarcinoma of the Pancreas or Periampullary Region
Pancreatic Neoplasms
Primary: Acute Toxicity Rates of Grade 3 or Greater Gastrointestinal and Hematologic Toxicities (as Raw Percentage) — 13.89; 0.00; 2.78; 0.00 percentage of participants
Phase 2 N=72 Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
Metastatic Pancreatic Cancer
Primary: Progression Free Survival With the Combination of GDC-0449 With Gemcitabine and Nab-paclitaxel. — 5.42 months
Phase 3 N=861 Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
Metastatic Pancreatic Cancer
Primary: Overall Survival (OS) — 8.5; 6.7 months — p=<0.0001
Phase 2 N=46 Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma
Risk for Colorectal Cancer
Primary: Number of Participants With Anti Muc-1 Antibody — 39 participants
Phase 2 N=13 Sunitinib in Never-Smokers With Lung Adenocarcinoma
Lung Cancer
Primary: Objective Response Rate (ORR) — 7.69 percentage of participants
Phase 2 N=54 Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma
Locally Advanced Pancreatic Adenocarcinoma
Primary: Number of Subjects With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 4; 23 Participants
Phase 2 N=119 Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung
Carcinoma, Non-small Cell
Primary: Progression-Free Survival (PFS) at Month 4: Cohort A — 76.9 percentage of participants
Phase 2 N=130 A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung
Adenocarcinoma of the Lung
Primary: Progression-free Survival (PFS) — 5.8; 4.7; 5.9; 4.7 Months — p=0.3519